Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000165337 | SCV000216060 | likely benign | Hereditary cancer-predisposing syndrome | 2014-08-05 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000198148 | SCV000253222 | likely benign | Neurofibromatosis, type 1 | 2025-01-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001557429 | SCV001779187 | likely benign | not provided | 2019-11-07 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001818378 | SCV002071878 | likely benign | not specified | 2021-09-21 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000198148 | SCV002560856 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002485024 | SCV002802190 | likely benign | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2021-08-10 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004552905 | SCV004757760 | likely benign | NF1-related disorder | 2019-10-10 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |